Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

By-health

SZSE:300146
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
300146
SZSE
CN¥26B
Market Cap
  1. Home
  2. CN
  3. Household
Company description

By-health Co., Ltd. produces and sells dietary supplements worldwide. The last earnings update was 25 days ago. More info.


Add to Portfolio Compare Print
300146 Share Price and Events
7 Day Returns
-2%
SZSE:300146
-1.5%
CN Personal Products
-0.1%
CN Market
1 Year Returns
-24.6%
SZSE:300146
-16%
CN Personal Products
-9.3%
CN Market
300146 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
By-health (300146) -2% -6.9% -4.8% -24.6% 50.9% -23%
CN Personal Products -1.5% -7.3% -4.4% -16% -21.6% -44.8%
CN Market -0.1% -10.6% -6.3% -9.3% -16.2% -26.5%
1 Year Return vs Industry and Market
  • 300146 underperformed the Personal Products industry which returned -16% over the past year.
  • 300146 underperformed the Market in China which returned -9.3% over the past year.
Price Volatility
300146
Industry
5yr Volatility vs Market

300146 Value

 Is By-health undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of By-health to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for By-health.

SZSE:300146 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year CN Government Bond Rate 3.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SZSE:300146
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CN Govt Bond Rate 3.2%
Equity Risk Premium S&P Global 6.3%
Personal Products Unlevered Beta Simply Wall St/ S&P Global 0.6
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.596 (1 + (1- 25%) (2.16%))
0.736
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.2% + (0.8 * 6.33%)
8.26%

Discounted Cash Flow Calculation for SZSE:300146 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for By-health is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

SZSE:300146 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CNY, Millions) Source Present Value
Discounted (@ 8.26%)
2020 459.00 Analyst x1 423.96
2021 1,353.00 Analyst x1 1,154.33
2022 1,564.00 Analyst x1 1,232.49
2023 1,724.81 Est @ 10.28% 1,255.47
2024 1,865.52 Est @ 8.16% 1,254.24
2025 1,989.95 Est @ 6.67% 1,235.77
2026 2,101.97 Est @ 5.63% 1,205.70
2027 2,204.98 Est @ 4.9% 1,168.24
2028 2,301.78 Est @ 4.39% 1,126.44
2029 2,394.62 Est @ 4.03% 1,082.42
Present value of next 10 years cash flows CN¥11,139.00
SZSE:300146 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CN¥2,394.62 × (1 + 3.2%) ÷ (8.26% – 3.2%)
CN¥48,800.29
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CN¥48,800.29 ÷ (1 + 8.26%)10
CN¥22,058.79
SZSE:300146 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CN¥11,139.00 + CN¥22,058.79
CN¥33,197.79
Equity Value per Share
(CNY)
= Total value / Shares Outstanding
= CN¥33,197.79 / 1,582.49
CN¥20.98
SZSE:300146 Discount to Share Price
Calculation Result
Value per share (CNY) From above. CN¥20.98
Current discount Discount to share price of CN¥16.36
= -1 x (CN¥16.36 - CN¥20.98) / CN¥20.98
22%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price By-health is available for.
Intrinsic value
22%
Share price is CN¥16.36 vs Future cash flow value of CN¥20.98
Current Discount Checks
For By-health to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • By-health's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • By-health's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for By-health's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are By-health's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SZSE:300146 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in CNY CN¥-0.24
SZSE:300146 Share Price ** SZSE (2020-04-03) in CNY CN¥16.36
China Personal Products Industry PE Ratio Median Figure of 13 Publicly-Listed Personal Products Companies 31.77x
China Market PE Ratio Median Figure of 3,197 Publicly-Listed Companies 32.34x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of By-health.

SZSE:300146 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SZSE:300146 Share Price ÷ EPS (both in CNY)

= 16.36 ÷ -0.24

-68.93x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • By-health is loss making, we can't compare its value to the CN Personal Products industry average.
  • By-health is loss making, we can't compare the value of its earnings to the China market.
Price based on expected Growth
Does By-health's expected growth come at a high price?
Raw Data
SZSE:300146 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -68.93x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
53.2%per year
China Personal Products Industry PEG Ratio Median Figure of 6 Publicly-Listed Personal Products Companies 2.44x
China Market PEG Ratio Median Figure of 1,273 Publicly-Listed Companies 1.27x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for By-health, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on By-health's assets?
Raw Data
SZSE:300146 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in CNY CN¥3.79
SZSE:300146 Share Price * SZSE (2020-04-03) in CNY CN¥16.36
China Personal Products Industry PB Ratio Median Figure of 15 Publicly-Listed Personal Products Companies 2.59x
China Market PB Ratio Median Figure of 3,691 Publicly-Listed Companies 2.26x
SZSE:300146 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SZSE:300146 Share Price ÷ Book Value per Share (both in CNY)

= 16.36 ÷ 3.79

4.32x

* Primary Listing of By-health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • By-health is overvalued based on assets compared to the CN Personal Products industry average.
X
Value checks
We assess By-health's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. By-health has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

300146 Future Performance

 How is By-health expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
53.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is By-health expected to grow at an attractive rate?
  • By-health's earnings growth is expected to exceed the low risk savings rate of 3.2%.
Growth vs Market Checks
  • By-health's earnings growth is expected to exceed the China market average.
  • By-health's revenue growth is expected to exceed the China market average.
Annual Growth Rates Comparison
Raw Data
SZSE:300146 Future Growth Rates Data Sources
Data Point Source Value (per year)
SZSE:300146 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 53.2%
SZSE:300146 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 18.2%
China Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 27.4%
China Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 16.7%
China Market Earnings Growth Rate Market Cap Weighted Average 20.9%
China Market Revenue Growth Rate Market Cap Weighted Average 15.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SZSE:300146 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SZSE:300146 Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 9,108 1,911 1,859 5
2021-12-31 7,889 1,721 1,645 9
2020-12-31 6,427 1,346 1,314 8
2020-04-06
SZSE:300146 Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2019-12-31 5,262 1,537 -358
2019-09-30 5,310 1,192 1,132
2019-06-30 5,151 1,238 1,161
2019-03-31 4,854 1,234 1,125
2018-12-31 4,351 1,349 999
2018-09-30 4,182 1,226 1,018
2018-06-30 3,794 1,084 885
2018-03-31 3,442 951 852
2017-12-31 3,111 954 763
2017-09-30 2,747 809 771
2017-06-30 2,562 772 759
2017-03-31 2,389 694 594

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • By-health's earnings are expected to grow significantly at over 20% yearly.
  • By-health's revenue is expected to grow by 18.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SZSE:300146 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from By-health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SZSE:300146 Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 1.18 1.24 1.11 5.00
2021-12-31 1.04 1.49 0.88 9.00
2020-12-31 0.84 0.90 0.80 7.00
2020-04-06
SZSE:300146 Past Financials Data
Date (Data in CNY Millions) EPS *
2019-12-31 -0.24
2019-09-30 0.77
2019-06-30 0.80
2019-03-31 0.78
2018-12-31 0.69
2018-09-30 0.70
2018-06-30 0.61
2018-03-31 0.59
2017-12-31 0.52
2017-09-30 0.53
2017-06-30 0.52
2017-03-31 0.41

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • By-health is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess By-health's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
By-health has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

300146 Past Performance

  How has By-health performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare By-health's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • By-health does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare By-health's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare By-health's 1-year growth to the CN Personal Products industry average as it is not currently profitable.
Earnings and Revenue History
By-health's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from By-health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SZSE:300146 Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 5,261.80 -358.43 2,077.61 126.04
2019-09-30 5,310.28 1,132.15 2,203.60 124.28
2019-06-30 5,150.88 1,161.50 2,022.64 121.92
2019-03-31 4,854.32 1,124.62 1,863.96 102.24
2018-12-31 4,350.78 999.25 1,680.56 103.49
2018-09-30 4,182.03 1,017.62 1,537.49 92.91
2018-06-30 3,793.92 885.15 1,379.72 110.33
2018-03-31 3,442.27 851.70 1,246.12 99.64
2017-12-31 3,110.80 762.81 1,208.42 77.26
2017-09-30 2,746.52 770.70 923.78 45.26
2017-06-30 2,562.32 758.70 891.25
2017-03-31 2,389.25 593.57 856.61
2016-12-31 2,309.11 535.21 882.73
2016-09-30 2,398.26 618.51 910.33
2016-06-30 2,322.33 577.36 914.73
2016-03-31 2,344.32 655.08 856.44
2015-12-31 2,266.04 635.50 824.95
2015-09-30 2,100.59 608.65 732.05
2015-06-30 1,943.86 566.36 658.62
2015-03-31 1,806.48 530.25 611.55
2014-12-31 1,704.98 502.59 567.08
2014-09-30 1,704.49 546.76 504.77
2014-06-30 1,668.06 541.89 480.45
2014-03-31 1,594.15 481.42 474.05
2013-12-31 1,482.24 421.69 465.53
2013-09-30 1,419.81 391.97 459.53
2013-06-30 1,290.86 333.51 445.91

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if By-health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if By-health has efficiently used its assets last year compared to the CN Personal Products industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if By-health improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess By-health's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
By-health has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

300146 Health

 How is By-health's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up By-health's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • By-health is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • By-health's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of By-health's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 6.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from By-health Company Filings, last reported 3 months ago.

SZSE:300146 Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 5,931.39 560.18 2,761.59
2019-09-30 7,325.70 944.63 2,272.93
2019-06-30 7,016.23 1,191.70 2,277.86
2019-03-31 6,615.51 1,464.92 2,902.90
2018-12-31 6,887.95 1,050.61 2,848.00
2018-09-30 7,054.94 1,065.83 1,307.17
2018-06-30 5,368.65 0.00 3,146.87
2018-03-31 5,025.00 0.00 2,850.62
2017-12-31 5,131.96 0.00 3,354.83
2017-09-30 5,152.78 0.00 2,908.21
2017-06-30 4,922.33 0.00 2,841.00
2017-03-31 4,608.33 0.00 2,217.49
2016-12-31 4,703.70 0.00 2,665.63
2016-09-30 4,679.31 260.00 1,917.30
2016-06-30 4,470.58 260.00 2,623.68
2016-03-31 4,336.72 260.00 1,605.12
2015-12-31 4,553.86 0.00 2,673.64
2015-09-30 4,517.92 0.00 1,467.11
2015-06-30 4,335.90 0.00 2,989.10
2015-03-31 4,119.34 0.00 2,878.61
2014-12-31 2,447.70 0.00 1,537.04
2014-09-30 2,425.27 0.00 1,513.19
2014-06-30 2,299.76 0.00 1,539.67
2014-03-31 2,088.23 0.00 1,629.24
2013-12-31 2,232.78 0.00 1,530.18
2013-09-30 2,149.48 0.00 1,351.51
2013-06-30 2,028.83 0.00 1,272.66
  • By-health's level of debt (9.4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if By-health's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (274.3%, greater than 20% of total debt).
  • By-health is making a loss, therefore interest payments are not well covered by earnings.
X
Financial health checks
We assess By-health's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. By-health has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

300146 Dividends

 What is By-health's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.2%
Current annual income from By-health dividends. Estimated to be 3.27% next year.
If you bought CN¥2,000 of By-health shares you are expected to receive CN¥44 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • By-health's pays a higher dividend yield than the bottom 25% of dividend payers in China (0.46%).
  • By-health's dividend is above the markets top 25% of dividend payers in China (2.03%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SZSE:300146 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
China Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.7%
China Market Average Dividend Yield Market Cap Weighted Average of 2588 Stocks 1.9%
China Minimum Threshold Dividend Yield 10th Percentile 0.2%
China Bottom 25% Dividend Yield 25th Percentile 0.5%
China Top 25% Dividend Yield 75th Percentile 2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SZSE:300146 Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
2022-12-31 0.76 4.00
2021-12-31 0.51 6.00
2020-12-31 0.41 6.00
2020-04-06
SZSE:300146 Past Annualized Dividends Data
Date (Data in CN¥) Dividend per share (annual) Avg. Yield (%)
2020-03-13 0.360 2.136
2019-02-28 0.500 2.728
2018-07-31 0.330 1.748
2017-03-31 0.260 1.975
2016-02-29 0.300 2.325
2015-04-02 0.250 1.427
2014-03-25 0.250 1.724
2013-02-28 0.100 0.711
2012-07-27 0.083 0.845
2012-02-01 0.083 0.938
2012-01-31 0.083 1.344
2011-10-20 0.042 0.626
2011-07-28 0.042 0.729
2011-07-27 0.083 1.590
2011-04-21 0.042 0.943
2011-04-18 0.042 0.928

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • By-health has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
  • Dividend payments have increased, but By-health only paid a dividend in the past 9 years.
Current Payout to shareholders
What portion of By-health's earnings are paid to the shareholders as a dividend.
  • The company is paying a dividend however it is incurring a loss.
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (1.6x coverage).
X
Income/ dividend checks
We assess By-health's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can By-health afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. By-health has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

300146 Management

 What is the CEO of By-health's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Zhicheng Lin
COMPENSATION CN¥522,000
AGE 51
TENURE AS CEO 5.6 years
CEO Bio

Mr. Zhicheng Lin has been Chief Executive Officer at By-health Co., Ltd. since September 26, 2014 and served as its Vice President and Secretary since June 2012 and since July 2012 respectively. Mr. Lin was Director of the investment and development center. He was senior Manager for Eastern region of China of LF Asia (FHBC) Ltd. from 2006 to 2011. He has been Non-Independent Director at By-health Co., Ltd. since September 26, 2014.

CEO Compensation
  • Zhicheng's compensation has increased whilst company is loss making.
  • Zhicheng's remuneration is lower than average for companies of similar size in China.
Management Team Tenure

Average tenure and age of the By-health management team in years:

5.6
Average Tenure
45
Average Age
  • The average tenure for the By-health management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Zhicheng Lin

TITLE
CEO & Director
COMPENSATION
CN¥522K
AGE
51
TENURE
5.6 yrs

Hong Chen

TITLE
Deputy General Manager
COMPENSATION
CN¥645K
AGE
53
TENURE
11.6 yrs

Liangping Cai

TITLE
Deputy General Manager
COMPENSATION
CN¥694K
AGE
45
TENURE
5.6 yrs

Zhuoyi Wu

TITLE
Chief Financial Officer
AGE
41
TENURE
3.2 yrs

Jinyin Tang

TITLE
Secretary to the Board of Directors
AGE
34
TENURE
2 yrs
Board of Directors Tenure

Average tenure and age of the By-health board of directors in years:

10.1
Average Tenure
51
Average Age
  • The average tenure for the By-health board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Yunchao Liang

TITLE
Chairman of the Board
COMPENSATION
CN¥645K
AGE
50
TENURE
11.6 yrs

Zhicheng Lin

TITLE
CEO & Director
COMPENSATION
CN¥522K
AGE
51
TENURE
5.6 yrs

Shuisheng Liang

TITLE
Vice Chairman
COMPENSATION
CN¥645K
AGE
54
TENURE
8.6 yrs

Gang Jiang

TITLE
Member of Supervisory Board
AGE
51
TENURE
11.6 yrs

Hui Tang

TITLE
Non-Independent Director
COMPENSATION
CN¥645K
AGE
51
TENURE
11.6 yrs

Heng Liu

TITLE
Independent Director
COMPENSATION
CN¥18K
AGE
55

Ping Zhang

TITLE
Independent Director
AGE
49

Wenjing Li

TITLE
Independent Director
AGE
40

Wen Wang

TITLE
Chairman of Supervisory Board
COMPENSATION
CN¥669K
AGE
53

Huizhen Shi

TITLE
Member of Supervisory Board
AGE
32
TENURE
2.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CN¥) Value (CN¥)
X
Management checks
We assess By-health's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. By-health has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

300146 News

Simply Wall St News

300146 Company Info

Description

By-health Co., Ltd. produces and sells dietary supplements worldwide. The company offers proteins and vitamins/minerals; and various products for skeleton and joints, heart and cerebral vessels, beauty maintenance, immunity boosting, weight management, vigor enhancement, eye nutrition, sleep improvement, blood glucose management, memory improvement, reproductive health, childhood nutrition, and pregnant women nutrition, as well as for liver, intestines, and stomach. It provides its products for children/teenagers, men, women, and middle aged and elderly people under the By-health and GymMax brand names through distributors, retail terminals, and online channels. The company was formerly known as Guangdong By-Health Biotechnology Co., Ltd. and changed its name to By-health Co., Ltd. in April 2012. By-health Co., Ltd. was founded in 1995 and is headquartered in Guangzhou, China.

Details
Name: By-health Co., Ltd.
300146
Exchange: SZSE
Founded: 1995
CN¥25,889,578,183
1,582,492,554
Website: http://www.by-health.com
Address: By-health Co., Ltd.
No. 3 Kehui Third Road,
No. 99, Kexue Avenue Middle,
Guangzhou,
Guangdong Province, 510663,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SZSE 300146 Domestic Shares Shenzhen Stock Exchange CN CNY 15. Dec 2010
XSEC 300146 Domestic Shares Shenzhen Stock Exchange - Shenzhen-Hong Kong Stock Connect CN CNY 15. Dec 2010
Number of employees
Current staff
Staff numbers
2,573
By-health employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 17:12
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/01
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.